drugset / Trial / NCT00548327

The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

NCT00548327

Phase 2 Terminated 11 enrolled National Institute of Mental Health (NIMH)
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain.

Timeline

Start
2007-10
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atomoxetine Other / unclassified 80 mg